Lundbeck to acquire Abide Therapeutics

Country

Denmark

H. Lundbeck A/S is poised to expand its portfolio of medicines for neurological diseases with the acquisition of Abide Therapeutics Inc, a US company whose lead product is being developed for Tourette syndrome and neuropathic pain. The product, ABX-1431, inhibits the serine hydrolase monoacylglycerol lipase (MGLL), a key enzyme in the brain.

According to the US National Cancer Institute, the compound has potential for use in the  treatment of various central nervous system (CNS) diseases because of its analgesic and anti-neuroinflammatory activities.